Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.

NCT Number	NCT07722962
Lead Sponsor	Kringle Pharma, Inc.
Conditions	Acute Spinal Cord Injury (SCI)
Enrollment	10 participants
Start Date	2026-07-31
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-23